Focal Segmental Glomerulosclerosis Market

Market Overview:

The 7 major focal segmental glomerulosclerosis markets reached a value of US$ 332.8 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 578.0 Million by 2034, exhibiting a growth rate (CAGR) of 5.15% during 2024-2034.

The focal segmental glomerulosclerosis market has been comprehensively analyzed in IMARC's new report titled "Focal Segmental Glomerulosclerosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Focal segmental glomerulosclerosis (FSGS) refers to a condition in which scar tissue forms on the glomeruli, the tiny part of the kidney responsible for removing waste from the blood. This results in damage to the kidney's filtration function and an abnormal loss of protein in the urine. The most common symptoms of the ailment include frothy urine, excess water retention, pitting edema, susceptibility to infection, fatty casts in the urine, etc. Individuals suffering from FSGS may also experience weight gain due to excess fluid building up in the body, high-fat levels in the blood, a poor appetite, fatigue, etc. The diagnosis typically involves a combination of laboratory investigations and imaging studies. A urine test helps in identifying the presence of proteinuria, while a blood test is performed to check for signs of kidney damage, such as elevated creatinine levels. Various imaging studies, including an ultrasound or CT scan, are utilized to visualize the kidneys and check for any abnormalities. Additionally, a renal biopsy, in which a small portion of the kidney is extracted using a special needle and examined under a microscope, is required to confirm the presence of FSGS among patients.

The rising prevalence of several associated risk factors, such as kidney infections, exposure to toxins, genetic mutations, underlying medical conditions like HIV and sickle cell disease, etc., is primarily driving the focal segmental glomerulosclerosis market. In addition to this, the widespread adoption of certain medications, including bisphosphonates, anabolic steroids, anthracyclines, calcineurin inhibitors, etc., that damage renal podocytes is also propelling the market growth. Furthermore, the inflating utilization of corticosteroids in the treatment of FSGS, which prevent the immune system from attacking the glomeruli and affecting renal function, is acting as another significant growth-inducing factor. Apart from this, the escalating application of plasmapheresis to reduce proteinuria and improve kidney function in patients is further creating a positive outlook for the market. Moreover, numerous key players are making extensive investments in R&D activities to launch innovative diagnostic techniques, such as next-generation sequencing technology, that provide higher specificity and sensitivity than conventional methods. This, in turn, is also bolstering the market growth. Additionally, the emerging popularity of anti-hypertensive therapy for treating the ailment since it can reduce the risk of further kidney damage and delay the need for more aggressive treatments, such as dialysis or kidney transplant, is expected to drive the focal segmental glomerulosclerosis market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the focal segmental glomerulosclerosis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for focal segmental glomerulosclerosis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the focal segmental glomerulosclerosis market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the focal segmental glomerulosclerosis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the focal segmental glomerulosclerosis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current focal segmental glomerulosclerosis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the focal segmental glomerulosclerosis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the focal segmental glomerulosclerosis market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the focal segmental glomerulosclerosis market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of focal segmental glomerulosclerosis across the seven major markets?
• What is the number of prevalent cases (2018-2034) of focal segmental glomerulosclerosis by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of focal segmental glomerulosclerosis by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with focal segmental glomerulosclerosis across the seven major markets?
• What is the size of the focal segmental glomerulosclerosis patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of focal segmental glomerulosclerosis?
• What will be the growth rate of patients across the seven major markets?
   

Focal Segmental Glomerulosclerosis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for focal segmental glomerulosclerosis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the focal segmental glomerulosclerosis market?
• What are the key regulatory events related to the focal segmental glomerulosclerosis market?
• What is the structure of clinical trial landscape by status related to the focal segmental glomerulosclerosis market?
• What is the structure of clinical trial landscape by phase related to the focal segmental glomerulosclerosis market?
• What is the structure of clinical trial landscape by route of administration related to the focal segmental glomerulosclerosis market?